图片 2

SA

图片 1AMX-30SA法国图片 2

如果支持我的工作,请帮忙领取支付宝红包

“目录号: HY-14814

  • 名称:AMX-30SA 30毫米双管自行高射炮
  • 研发单位:武器研究与制造局
  • 口径:小口径炮

免费账号

注册后每月签到一次可获得1G流量,不要在网站购买,需要节点私聊我

Anti-infection-

技术数据

  • 口径:30毫米
  • 总重:35,000千克

  法国武器研究与制造局研制的口径30毫米的双管自行式高射炮。1975年生产,出口沙特阿拉伯。

客户端

Android
Windows

密码:1111

Delafloxacin (RX-3341, ABT-492)是氟喹诺酮类抗生素。

结构特点

该炮由30毫米自动炮,TG230A式炮塔,AMX-30坦克底盘,“绿眼”雷达,光学瞄准具和火控计算机等组成。主要构造均与AMX-13DCA30毫米双管自行高射炮相同。

使用教程

Android
Windows
Linux

Bacterial

主要用户

  • 沙特阿拉伯

相关产品

G-418
disulfate-Anisomycin-Salinomycin-Avibactam
sodium-Vancomycin
hydrochloride-Hygromycin
B-Bleomycin
sulfate-Ciprofloxacin-Minocycline
hydrochloride-Ampicillin
sodium-Tetracycline
hydrochloride-Tebipenem-Kanamycin
sulfate-Solithromycin-Tedizolid-

生物活性

Description

Delafloxacin (RX-3341, ABT-492) is a fluoroquinolone antibiotic
agent.IC50 Value: MICs ranging from 0.0078 to 0.125 micro g/ml for
levofloxacin-resistant Streptococcus pneumoniae strains [1]Target:
AntibacterialABT-492 was more potent against quinolone-susceptible and
-resistant gram-positive organisms, had activity similar to that of
ciprofloxacin against certain members of the family Enterobacteriaceae,
and had comparable activity against quinolone-susceptible,
nonfermentative, gram-negative organisms.in vitro: ABT-492 exhibited
excellent in vitro activities against all 326 aerobic and anaerobic
antral puncture sinus isolates tested with MICs (in micrograms per
milliliter) at which 90% of the isolates tested were inhibited as
follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008;
and Streptococcus pneumoniae, 0.015 [2]. ABT-492 was as active as
trovafloxacin against Chlamydia trachomatis, indicating good
intracellular penetration and antibacterial activity [3].in vivo:
Clinical trial: N/A

Clinical Trial

NCT02505997

Melinta Therapeutics, Inc.

VA Drug Interactions

June 2015

Phase 1

NCT02245243

Melinta Therapeutics, Inc.

Hepatic Impairment

September 2014

Phase 1

NCT02679573

Melinta Therapeutics, Inc.

Community Acquired Bacterial Pneumonia

December 14, 2016

Phase 3

NCT02015637

Melinta Therapeutics, Inc.

Gonorrhea

January 2014

Phase 3

NCT01984684

Melinta Therapeutics, Inc.

Skin and Subcutaneous Tissue Bacterial Infections-Skin Structures and
Soft Tissue Infections

May 2014

Phase 3

NCT01811732

Melinta Therapeutics, Inc.

Skin and Subcutaneous Tissue Bacterial Infections

April 2013

Phase 3

NCT01283581

Melinta Therapeutics, Inc.

Skin and Subcutaneous Tissue Bacterial Infections

January 2011

Phase 2

NCT00719810

Melinta Therapeutics, Inc.

Skin Structure Infections-Bacterial Skin Diseases-Staphylococcal Skin
Infections

June 2008

Phase 2

View MoreCollapse

References

[1].Gunderson SM, Hayes RA, Quinn JP, In vitro pharmacodynamic
activities of ABT-492, a novel quinolone, compared to those of
levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae,
and Moraxella catarrhalis. Antimicrob Agents Chemother. 2004
Jan;48(1):203-8.

[2].Goldstein EJ, Citron DM, Merriam CV, In vitro activities of
ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic
pathogens isolated from antral sinus puncture specimens from patients
with sinusitis. Antimicrob Agents Chemother. 2003
Sep;47(9):3008-11.

[3].Nilius AM, Shen LL, Hensey-Rudloff D, In vitro antibacterial
potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob
Agents Chemother. 2003
Oct;47(10):3260-9.